Avivagen (OTCMKTS:VIVXF) versus Capricor Therapeutics (NASDAQ:CAPR) Critical Contrast

Avivagen (OTCMKTS:VIVXF) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for Avivagen and Capricor Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avivagen	0	0	0	0	0.00
Capricor Therapeutics	1	0	9	0	2.80

Capricor Therapeutics has a consensus target price of $48.36, suggesting a potential upside of 67.52%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Avivagen.

Insider & Institutional Ownership

21.7% of Capricor Therapeutics shares are held by institutional investors. 2.1% of Avivagen shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Avivagen and Capricor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avivagen	N/A	N/A	N/A
Capricor Therapeutics	N/A	-59.27%	-48.65%

Valuation & Earnings

This table compares Avivagen and Capricor Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avivagen	N/A	N/A	N/A	($0.04)	N/A
Capricor Therapeutics	$22.27 million	75.07	-$105.04 million	($2.32)	-12.44

Avivagen has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Avivagen, indicating that it is currently the more affordable of the two stocks.

Summary

Capricor Therapeutics beats Avivagen on 6 of the 9 factors compared between the two stocks.

About Avivagen

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.